Clinical Trial Update: Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma

View source ↗

Summary

Clinical trial update: vorasidenib is being studied for CNS WHO Grade 2 IDH-mutant diffuse glioma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idh-mutant Diffuse Glioma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: iOMEDICO AG | Conditions: Glioma | Status: RECRUITING